Delving Into Participation Trends in Renal Cell Carcinoma Studies
Part of paid clinical trials in San Francisco, California.
- Sponsor
- Power Life Sciences Inc.
- Study ID
- NCT06093568
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Study Details
The study seeks to delve into the firsthand experiences of patients diagnosed with renal cell carcinoma who partake in a separate clinical study featuring a specific medical intervention. The primary emphasis will be on meticulously tracking the rates of trial completion and withdrawal among these individuals. By joining this clinical trial, individuals have the unique opportunity to contribute to the betterment of future renal cell carcinoma patients and play an active role in advancing clinical research.
Key Dates
- Start date
- Nov 30, 2024
- Status verified
- Oct 2023
- Primary completion
- Nov 30, 2025
- Completion
- Nov 30, 2026
Study Design
- Enrollment
- 500 participants (estimated)
Primary Outcome Measure
Number of patients who decide to participate in a renal cell carcinoma clinical study [ Time Frame: 3 months ]
Central Contacts
- Michael B Gill4159004227
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Power Life Sciences | San Francisco | California | 94107 |
Find similar trials in San Francisco, CA
Related Studies
- A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)PHASE3 · Recruiting · Xynomic Pharmaceuticals, Inc. · Phoenix, Arizona
- A Multicenter Cancer Biospecimen Collection StudyRecruiting · Cofactor Genomics, Inc. · San Francisco, California
- Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney CancerPHASE2 · Recruiting · National Cancer Institute (NCI) · La Jolla, California
- ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy EvaluationRecruiting · Guardant Health, Inc. · Birmingham, Alabama